SUZHOU, China, Nov. 10, 2025 /PRNewswire/ — A news report from Xinhua Finance:

The 2025 Automotive Technology and Equipment Development Forum was held in Suzhou from November 6 to 8. Framed around the theme “Equipment as the Foundation, Technology as the Path Forward”, the event was jointly organized by the Equipment Industry Development Center (EIDC) under the Ministry of Industry and Information Technology, the Suzhou Municipal People’s Government, and China Automotive Engineering Research Institute Co. Ltd. (CAERI). The forum served as a venue for policy briefings, technical exchanges, showcases of applied results, and matchmaking sessions—with the aim of transitioning the auto sector toward closer integration of manufacturing equipment with intelligent technologies and building an industry ecosystem that is open, partnership-based, and aimed at shared gains.

During the forum, the EIDC released the “China Automotive Industry and Technology Development Report (2025)”. The report said China’s automotive industry has posted notable gains in recent years and has been a steadying factor for the broader industrial economy. From January to September this year, nationwide automobile output and sales came in at 24.333 million and 24.363 million units, respectively, up 13.3% and 12.9% year-on-year. The electric-vehicle segment stood out in particular, with production reaching 11.243 million units and sales 11.228 million units over the same period—more than 35% higher and accounting for 46.1% of all new passenger- and commercial-vehicle combined sales.

Looking ahead to the future of the automotive industry, several industry experts at the forum offered systematic recommendations. Su Bo, Director of the National Expert Committee on Intelligent Manufacturing and former Vice Minister of the Ministry of Industry and Information Technology, said China needs to channel resources toward clearing core technology chokepoints, notably automotive-grade chips, high-safety solid-state batteries, and in-vehicle operating systems. He added that China should make fuller use of national-level science and technology platforms, including the National Innovation Center of Intelligent and Connected Vehicles, to make sure it keeps control over the pace and direction of technology upgrades.

The forum also saw the launch of a series of initiatives aimed at strengthening the global competitiveness of China’s auto industry. These include the “Standards Lead the Way, Quality Drives the Future” campaign, which seeks to lift the international profile of Chinese auto brands through tighter and more export-ready quality benchmarks; the “China Chip” Joint Research Lab, set up to reinforce China’s semiconductor capabilities for intelligent and connected electric vehicles; the “Upgrading Automotive Manufacturing with Domestic High-End Equipment” program, designed to raise quality and efficiency through the use of domestically produced advanced machinery; and the “15^th Five-Year Plan Synergy for Automotive Technology and Equipment” initiative, which is intended to keep future advances in vehicle technology and supporting industrial equipment on the same track. Taken together, these measures are expected to add momentum to priority areas such as quality, chips, and high-end equipment—key drivers shaping the industry’s future. 

RAICHUR, India, Nov. 11, 2025 /PRNewswire/ — Shilpa Pharma Lifesciences Limited, a material subsidiary of Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), has been awarded the prestigious Gold Medal by EcoVadis, the world’s most trusted provider of business sustainability ratings.

The company achieved an exceptional score of 82/100, placing it in the 98th percentile globally among 130,000 + companies evaluated by EcoVadis. This performance underscores our industry-leading Environmental, Social and Governance (ESG) practices and reflects our long-term commitment to building a responsible, resilient, and sustainable pharmaceutical enterprise.

EcoVadis assesses organizations on four key pillars — Environment, Labor & Human Rights, Ethics, and Sustainable Procurement — and this recognition positions Shilpa Pharma Lifesciences among the top few global companies rated for sustainable business operations.

Speaking on this milestone, Mr. Keshav Bhutada, ED & CEO of Shilpa Pharma Lifesciences emphasized that “Sustainability and innovation are integral to Shilpa’s CDMO growth strategy to work with global innovator companies for their New chemical Entity programs. The EcoVadis Gold Medal is a testimony to our relentless efforts toward responsible manufacturing, ethical governance, and inclusive growth that creates enduring value for patients and partners. We look forward to work with more global innovator companies”

This achievement further strengthens Shilpa’s credentials with global customers, investors, and partners, reinforcing their positioning as a trusted global CDMO partner with sustainability at the core of their operations.

About Shilpa Medicare Limited

Shilpa Medicare Limited (BSE: 530549 | NSE: SHILPAMED) is a leading Indian pharmaceutical company focused on the development, manufacture, and marketing of APIs, formulations, and biologics across oncology, infectious diseases, and specialty segments. With expertise in complex generics, novel drug delivery systems, and CDMO services, Shilpa serves patients in over 80 countries. For more information, visit www.vbshilpa.com

Forward-Looking Statement Disclaimer

This document contains forward-looking statements describing the Company’s objectives, plans, and expectations for future performance. Actual results may differ materially due to risks and uncertainties including regulatory approvals, clinical outcomes, market conditions, and competitive developments. Shilpa Medicare undertakes no obligation to update forward-looking statements to reflect subsequent events or circumstances.

TAIPEI, Nov. 11, 2025 /PRNewswire/ — GLAC Biotech, a leading innovator in probiotics and postbiotics research, proudly announces another milestone on the global stage. Its flagship strain, Lactobacillus plantarum PL-02, has been honored with two major awards at the 7th iSEE Global Innovation Awards, recognizing its outstanding scientific validation and breakthrough applications in both brain health and sports nutrition.

Scientifically Proven: The Power of PL-02

Derived from the microbiome of an Olympic gold medalist, PL-02 represents the fusion of athletic vitality and advanced scientific research. Extensive studies have demonstrated PL-02’s exceptional acid and bile tolerance, intestinal colonization ability, and its multi-faceted benefits for energy metabolism, physical performance, and gut-brain health.

Through years of rigorous R&D, GLAC Biotech has established PL-02 as a next-generation functional probiotic, setting new standards in evidence-based innovation.

Double Awards for Scientific Excellence

Two functional probiotic ingredients developed from PL-02 stood out among global competitors to win dual recognition at the iSEE Awards:

PRONULIFE® IntBrain — A brain-health probiotic that supports focus, cognitive performance, and emotional balance through gut-brain axis modulation.

PRONULIFE® Effenergy — A sports-performance probiotic that enhances endurance, accelerates recovery, and optimizes energy utilization.

These twin honors mark a major international endorsement of PL-02’s proven efficacy and underline GLAC Biotech’s global leadership in probiotic innovation.

iSEE Global Recognition — Taiwan’s Scientific Pride

Known as the “Oscars of the Health Industry,” the iSEE Global Innovation Awards celebrate products that combine innovation, efficacy, and scientific rigor.PL-02’s double victory not only highlights its strong clinical foundation but also positions Taiwan’s biotech research at the forefront of the global probiotic industry.“PL-02 is more than a probiotic strain — it embodies the spirit of scientific excellence and human performance,” said GLAC Biotech.
“This recognition affirms our long-term commitment to clinical validation and global collaboration in functional probiotics.”

Looking Ahead: Expanding the Frontier of Functional Health

GLAC Biotech will continue advancing research on PL-02 to expand its applications in brain health, sports performance, and energy metabolism, while fostering global partnerships to bring Taiwan-origin probiotic innovations to the world.

Event Preview｜Natural Extracts & Health Ingredients Exhibition (FIC-Health 2025) & the 24th National Food Additives and Ingredients Exhibition

Date: November 26–28, 2025
Booth: 10B58
Seminar: November 27, 11:00 AM ｜ Meeting Room 4
Topic: “Unlocking the Mind-Body Frontier — PL-02 Probiotic, a New Choice for Cognitive and Athletic Performance.”

TOKYO, Nov. 11, 2025 /PRNewswire/ — Ergotron, a global leader in workspace ergonomics, today announced the LX Pro Monitor Arm is now available in Japan. This latest generation is specially designed for evolving workspace technologies and hybrid environments. It offers flexible configurations for customized ergonomics, streamlined installation, and extensive longevity, making it the ideal solution for optimizing both wellbeing and productivity as Japan embraces flexible work arrangements. Following its earlier US debut, LX Pro has already been recognized as Best Monitor Arm by PC World.

Empowering Japan’s shift towards flexible work

According to Nikkei Asia, 61% of Japanese workers now describe their work environment as hybrid — the second-highest in Asia. As Japan continues to lead the shift to hybrid work and free-address office models, companies and workers require flexible tools that optimize wellbeing and productivity. To deliver this, LX Pro empowers companies and home users to create ergonomic, personalized setups that adapt seamlessly to different workflows and work styles.

Mr. Masashi Yamashita, Japan Country Manager, Ergotron, commented: “Japan is at the forefront of redefining global norms around how and where work happens. To facilitate this transformation, LX Pro gives Japanese workers and managers the ability to customize workspaces — whether in free-address offices or at home — to achieve optimal comfort and productivity. We are pleased to bring this level of ergonomic innovation to Japan at a time when it is more important than ever.”

Industry-leading longevity, versatility, and ergonomics

Backed by more than 20 years of ergonomic expertise and a ten-year warranty, Ergotron’s LX Pro is a modular, upgradeable platform that is the perfect future-proof solution for modern workspaces. Its sleek, timeless design, with Matte Black and White color options, blends seamlessly with various environments, and it offers the unrivaled versatility to pair with multiple monitor sizes and configurations. It also delivers:

Easy setup

• Quick three-step assembly with detachable head
• Integrated cable management covers
• NEW tension indicator for faster setup and office-wide deployment
• NEW rotation stop prevents contact with walls or partitions

Enhanced ergonomics

• Industry-leading tilt range from 70° to -15° for customizable positioning to optimize posture
• Constant Force™ technology ensures smooth, long-lasting adjustability

Learn more below:
LX Pro official product page
Press Kit
Purchase directly at:
Amazon
Rakuten
Yahoo

About Ergotron

Ergotron’s mission is to empower movement and drive productivity, health, and well-being in workspaces across various sectors. We’re dedicated to advancing innovative, ergonomic solutions that meet evolving needs, from healthcare and education to manufacturing and office environments. By delivering adaptable, high-quality products, we aim to make workspaces more comfortable, sustainable, and responsive to the needs of today’s workforce.

Ergotron is headquartered in St. Paul, Minnesota, with a presence in North America, EMEA and Asia Pacific. For more information, please visit www.ergotron.com/ja-jp.

Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections

RAICHUR, India, Nov. 11, 2025 /PRNewswire/ — Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED) announced the successful completion of its fourth complex clinical program SMLINJ011, with positive topline Phase 3 results for Shilpa’s OERIS™ (Ondansetron Extended-Release Injection)—an innovative formulation designed to improve prophylaxis of chemotherapy-induced nausea and vomiting (CINV).

This milestone underscores Shilpa’s growing leadership in differentiated drug-delivery systems and oncology supportive-care therapeutics, reflecting the company’s commitment to advancing patient-centric innovation.

Study Overview

A Phase III, multicenter, randomized, double-blind, non-inferiority trial was conducted across multiple oncology centers in India to compare OERIS™ with conventional ondansetron injections in 240 patients receiving moderately or highly emetogenic chemotherapy.

Design & Endpoints

• Population: 240 patients with CINV
• Primary Endpoint: Complete response (no emesis episodes through 120 hours post-chemotherapy)
• Comparator: Multiple doses of conventional ondansetron injection
• Secondary Endpoints: Safety profile, delayed-phase response, patient tolerability

Results

• Complete response: 89% in OERIS™ arm vs. 82% in standard ondansetron arm
• Adverse events: No serious or severe adverse events reported
• Safety: Comparable or better tolerability than conventional therapy

Transformative Innovation
OERIS™ offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days, eliminating the need for multiple daily doses or oral follow-ups. This innovation enhances patient convenience, improves compliance, and streamlines clinical workflow.

“We are proud to announce the successful completion of this pivotal Phase 3 study,” said Mr. Vishnukant Bhutada, Managing Director, Shilpa Medicare Limited. “OERIS™ exemplifies Shilpa’s ability to combine scientific innovation with patient-centric design, strengthening our oncology-supportive-care portfolio and our vision to become a global leader in specialty pharmaceuticals.”

Next Steps
Shilpa plans to file for regulatory approval with the DCGI and pursue global registration and commercialization through the 505(b)(2) pathway in the US and other key markets.

About CINV
CINV affects up to 70–80% of patients undergoing chemotherapy, representing a market of approximately USD 375 million. Poorly controlled CINV can lead to treatment discontinuation and reduced quality of life, underscoring need for long-acting therapies such as OERIS™.

About Shilpa Medicare Limited
Shilpa Medicare is a leading Indian pharmaceutical company specializing in APIs, formulations, and biologics across oncology and specialty segments. For more information, visit www.vbshilpa.com.

SINGAPORE, Nov. 11, 2025 /PRNewswire/ — Co-funded by the European Union and CNIEL, Europe Full of Character returns for a final, delicious year in Singapore with “Cheese Eat Up!”, a celebration of French cow’s milk cheeses and their unique ability to elevate and harmonize with local cuisine.

This third and final chapter of the campaign invites Singaporeans to rediscover beloved street food through the rich, creamy, and complex world of French cheese. From hawker classics reimagined with a cheesy twist to sophisticated gourmet interpretations, the campaign proudly bridges French tradition with Singapore’s dynamic culinary creativity.

“It has been an honour to lead this campaign over the past three years. Watching the local industry embrace French cheese with such enthusiasm has been incredibly rewarding.
Singapore is a vibrant, dynamic market with enormous potential for the future of authentic French dairy.”
— Émilie Martin, Managing Director, CNIEL

A Culinary Crossroads: French Cheese Meets Singaporean Soul

Over the last three years, Europe Full of Character has trained future chefs from institutions like ITE, At-Sunrice, CIA, and SHATEC, while partnering with importers, chefs, and distributors to showcase the versatility of iconic French cow’s milk cheeses such as Brie, Camembert, Mimolette, Comté, and Bleu d’Auvergne.

This year’s campaign highlights how these cheeses not only complement but elevate Singapore’s rich tapestry of flavours, melding effortlessly with bold spices, fresh herbs, and vibrant textures typical of local dishes. French cheese’s natural creaminess and nuanced depth add a luxurious layer that both balances and enhances the complex flavour profiles beloved by Singaporeans.

“French cheeses have everything it takes to enhance local favourites: they melt beautifully, balance strong spices, and bring natural creaminess. They’re also deliciously simple and minimally processed,” explains François Robin, one of France’s best cheesemongers. “In Singapore, where food is a melting pot of cultures, French cheese adds a distinctive European elegance without overpowering the soul of the dish.”

Industry Feedback: What Guests Are Saying

The campaign’s shift to an interactive masterclass format this year brought fresh energy and inspiration:

• “The content was rich and inspiring. François Robin made everything feel approachable. Tasting the recipes and seeing the cheese platter come together live was a real highlight.” — R. E., Category Manager
• “A dynamic, well-organised event with lots of opportunities to connect. I left with concrete ideas and great new contacts in the industry.” — A. M., Sales Manager
• “I truly rediscovered French cheese. The pairings were unexpected and absolutely delicious.” said a participating influencer from our recent campaign.

Hero Recipe

Why it works:
Comté’s rich, nutty character and melt-in-your-mouth texture perfectly complement the spicy, aromatic curry filling, a quintessential Singaporean snack. This fusion dish showcases how French cheese can harmonize with local ingredients, balancing the sweet, tangy, and pickled elements that define Singapore’s hawker favourites. The elegant vol-au-vent shell elevates the humble curry puff into a refined, modern bite, symbolizing the seamless blend of French sophistication and Singaporean street food culture.

Prep Time: 25 mins
Cook Time: 20 mins
Makes: 12

FILLING

• 250g waxy potatoes, diced
• 1 small red onion, chopped
• 1 garlic clove, minced
• 1 tsp grated ginger
• 2 tbsp ghee
• 1½ tsp curry powder
• ¼ tsp turmeric
• 60g Comté, grated
• Salt & pepper

TOPPINGS

• 2 tbsp sesame seeds, toasted
• 50g quick-pickled vegetables
• 2 tbsp sweet chilli sauce

TO SERVE

• 12 ready-made vol-au-vent shells
• 20g Comté, shaved
• Coriander for garnish

Instructions:

1. Sauté onion in ghee, then add garlic, ginger, and spices.
2. Add diced potatoes with a splash of water. Cover and steam for 10 mins.
3. Lightly mash and mix in grated Comté.
4. Toast sesame seeds in a dry pan.
5. Fry vol-au-vent shells until crisp.
6. Fill with warm potato mix. Top with pickled veg, chilli sauce, sesame seeds, coriander, and shaved Comté.

Campaign Highlights

• Trade & Media Showcase: Featuring hawker-style dishes reimagined with French cheese led by François Robin, one of the Best French Cheesemongers
• Culinary Workshops: Led by Chef Maryjoy Lym from JAG (1 Michelin Star), exploring cheese board design and local mocktail fusion
• Cheese Pairing Inspiration: Through social media, recipes, and tastings across the city

Follow us: @cheesycharacters_sg

About CNIEL
CNIEL (Centre National Interprofessionnel de l’Économie Laitière) champions French dairy worldwide, promoting sustainable practices and sharing French expertise through education and international outreach.